An observational study in Rectal Diseases, Rectal Neoplasms and Gastrointestinal Diseases, sponsored by University Hospital, Akershus. Completed at 1 site in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-19.
Sponsored by University Hospital, Akershus · Observational
Among 25 studies in Rectal Neoplasms with a site in Norway — 6 open to participants now, 12 under way, 3 of them phase 3. Rectal Neoplasms · Norway.
Among the 25 studies in Rectal Neoplasms with a site in Norway, this one is the 6th largest by enrollment of the 11 observational ones, is one of 2 that started in 2013, is one of 11 observational ones, and was the 8th registered.
2,400 studies on the registry are indexed under Rectal Neoplasms; 587 are open to participants now.
This study's enrollment of 192 is above the median of 161 across 498 observational studies indexed under Rectal Neoplasms.
Browse Rectal Neoplasms studies →6 of the 25 studies in Rectal Neoplasms with a site in Norway are open now, in 10 countries. Each count lists the studies.
Of the 404 Rectal Neoplasms studies recruiting now, 210 (52%) set no upper age limit and 142 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →25 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 2 started in 2013.
Median enrollment 106 across the 13 interventional studies, 192 across the 11 observational. Of the 12 that completed or were terminated, 1 (8%) have results posted.
3 of 25 have an industry lead sponsor. The 10 most frequent:
University Hospital, Akershus is the lead sponsor of 125 studies on the registry; 28 are open to participants now.
University Hospital, Akershus has 1 study filed under Rectal Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies in Rectal Neoplasms with a site in Norway that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04726800Anna MartlingCirculating Tumour DNA (ctDNA) as a Prognostic and Predictive Marker in Colorectal Cancer - a Pilot Study | 2026-12 |
| NCT05883800Haukeland University HospitalTotal Neoadjuvant Treatment Combined With Adaptive Radiotherapy for Rectal Cancer | 2026-12-31 |
| NCT04512937Oslo University HospitalComputer Navigation-assisted Surgery for Locally Advanced and Recurrent Rectal Cancer | 2027-09-01 |
Among the 25 studies in Rectal Neoplasms with a site in Norway, from their registry updates:
Nothing recorded among them since 2026-09-25.
The purpose of this study is to establish a reliable method for detection of rectal cancer patients with aggressive tumor at risk of metastatic disease and death by functional MRI.
2,400 studies on the registry are indexed under Rectal Neoplasms; 587 are open to participants now.
This study's enrollment of 192 is above the median of 161 across 498 observational studies indexed under Rectal Neoplasms.
Browse Rectal Neoplasms studies →University Hospital, Akershus is the lead sponsor of 125 studies on the registry; 28 are open to participants now.
Compared within Rectal Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Rectal Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Rectal cancer patients referred to radical surgery, with or without preoperative chemoradiotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Procedure: new functional magnetic resonance imaging (MRI) protocols
diffusion-weighted MRI, dynamic-contrast enhanced MRI, MR spectroscopy, blood-level oxygen dependent (BOLD) MRI
Presence of metastatic disease 5 years after rectal cancer treatment
Time frame: five years
Histomorphological response to preoperative chemoradiotherapy
Time frame: 8 weeks
Detection of regional malignant lymph nodes at time of diagnosis
Time frame: 8 weeks
The record gives a start of Oct 2013, a primary completion of Dec 2017 and a completion of Dec 2017. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Akershus →